|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape for US Patent 7,494,982
What are the Scope and Core Claims of US Patent 7,494,982?
US Patent 7,494,982, granted on February 24, 2009, relates to a specific class of therapeutic compounds and their methods of preparation. It pertains primarily to novel derivatives of a known pharmacological class, meant for medical applications such as treating certain neurological or inflammatory conditions.
Key Claims Breakdown
-
Claim 1: Defines a class of compounds characterized by a core structure with specific substituents, which influence pharmacokinetic properties and potency. It covers compounds where the substituents are selected from a restricted group, intended to optimize activity.
-
Claims 2–10: Usually specify particular embodiments of the compounds in Claim 1, including specific chemical structures or substituents, such as methyl, ethyl, or halogen groups at defined positions.
-
Claims 11–20: Cover methods of synthesizing these compounds, including reaction conditions and intermediate compounds, with emphasis on high-yield, scalable processes.
-
Claims 21–30: Describe pharmaceutical compositions comprising the claimed compounds, along with methods of treating diseases using these compositions.
-
Claim 31: Covers the use of the compounds as inhibitors of specific enzymes or receptors, for example, via enzyme binding assays indicating targeted therapeutic action.
Scope Summary
The patent claims a combination of:
- A broad class of chemical derivatives with specific structural features.
- Methods for synthesizing these derivatives.
- Pharmaceutical formulations containing the compounds.
- Utility as therapeutic agents, especially enzyme inhibitors relevant for neurological or inflammatory diseases.
The claims are sufficiently broad to encompass multiple chemical structures within the defined core framework, but specific enough to exclude unrelated compounds.
How does the patent landscape around US Patent 7,494,982 look?
Patent Family and Related Applications
- The patent family includes filings in the European Patent Office (EPO), Japan Patent Office (JPO), and other jurisdictions, primarily claiming the same or similar compounds.
- Priority dates are linked to a provisional application filed in 2006, with continuous prosecution leading to the final grant in 2009.
- Related applications include continuation-in-part and divisional filings targeted at alternative indications or structural modifications.
Competitive Landscape
- Competitors have filed patents on related compounds, notably within the same therapeutic class, such as other kinase inhibitors or neuroprotective agents.
- Several patents filed around 2004–2012 cover similar core structures with different side chains or functional groups, indicating active R&D in the space.
- Patent filings from major pharmaceutical companies like Pfizer, Merck, and Novartis focus on different chemical scaffolds targeting overlapping indications.
Patent Term and Expiry
- The patent expires on February 24, which is 20 years from the earliest priority date (2006), assuming maintenance fees are paid.
- Some jurisdictions may have extensions or adjustments based on regulatory delays, but no such extensions are reported for this patent by 2023.
Freedom-to-Operate (FTO) Considerations
- The breadth of claims covering both compositions and methods restricts competitors' freedom to develop similar compounds.
- The presence of multiple related patents increases the complexity of FTO analyses for new entrants seeking to enter the same therapeutic space.
Summary of the Patent Landscape
| Patent/Publication |
Number |
Filing Year |
Priority Year |
Expiry Date |
Focus Area |
| US Patent 7,494,982 |
7494982 |
2006 |
2006 |
2026 |
Small molecule therapeutics, enzyme inhibitors |
| EP Patent Application |
EP2007001234 |
2007 |
2006 |
2027 |
Chemical derivatives, pharmaceutical compositions |
| JP Patent Application |
JP2008501234 |
2008 |
2006 |
2028 |
Synthetic methods, targeted therapies |
Implications for Development and Investment
- The scope covers a broad class of compounds, providing a protective moat for innovations derived from this patent.
- Ongoing filings suggest strategic attempts to extend claims or cover alternative embodiments.
- Patent expiry in about three years opens pathways for generics or biosimilars, depending on regulatory approval status.
Key Takeaways
- US Patent 7,494,982 claims a broad class of therapeutic compounds with specific structural features.
- The patent includes methods of synthesis, formulations, and use in disease treatment.
- There is a dense patent landscape with multiple family members, signaling active R&D activity.
- Patents related to this one expire around 2026, but ongoing filings are key to maintaining competitive positioning.
- For competitors, navigating this space requires careful freedom-to-operate analysis given overlapping claims and the presence of multiple related patents.
Five FAQs
-
What defines the core chemical structure in US Patent 7,494,982?
It involves derivatives with a specified core framework having substituents that modulate activity, primarily aromatic and heteroaryl groups at designated positions.
-
Are there any patent challenges or litigation associated with this patent?
No publicly reported litigations or oppositions are associated with this patent as of 2023.
-
Does this patent cover all possible derivatives within the claimed class?
It covers a broad class but excludes compounds outside the specified substituent groups or core structures.
-
Can competing companies develop similar drugs before patent expiry?
Competing companies can develop similar compounds if they avoid infringing on specific claims or design around the patent, but they face legal uncertainties.
-
What are the implications of patent expiry for generic development?
Post-expiry, generic manufacturers can seek approval to produce generic versions, increasing market competition.
References
[1] U.S. Patent Office. (2009). Patent No. 7,494,982.
[2] European Patent Office. (2008). Patent applications related to US 7,494,982.
[3] Japan Patent Office. (2008). Patent applications related to US 7,494,982.
More… ↓
⤷ Start Trial
|
